HomeCompareSCPH vs PFE

SCPH vs PFE: Dividend Comparison 2026

SCPH yields 35.27% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCPH wins by $127.5K in total portfolio value
10 years
SCPH
SCPH
● Live price
35.27%
Share price
$5.67
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.6K
Annual income
$27,157.20
Full SCPH calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — SCPH vs PFE

📍 SCPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSCPHPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SCPH + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SCPH pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SCPH
Annual income on $10K today (after 15% tax)
$2,998.24/yr
After 10yr DRIP, annual income (after tax)
$23,083.62/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $45.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SCPH + PFE for your $10,000?

SCPH: 50%PFE: 50%
100% PFE50/50100% SCPH
Portfolio after 10yr
$114.8K
Annual income
$27,183.87/yr
Blended yield
23.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SCPH
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Price Target
$8.12
+43.2% upside vs current
Range: $5.35 — $13.00
Altman Z
-7.3
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SCPH buys
0
PFE buys
0
No recent congressional trades found for SCPH or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSCPHPFE
Forward yield35.27%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$178.6K$51.1K
Annual income after 10y$27,157.20$27,210.54
Total dividends collected$129.2K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$8.12$27.50

Year-by-year: SCPH vs PFE ($10,000, DRIP)

YearSCPH PortfolioSCPH Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$14,227$3,527.34$9,161$701.38+$5.1KSCPH
2$19,913$4,690.15$8,610$859.79+$11.3KSCPH
3$27,442$6,135.14$8,366$1,081.25+$19.1KSCPH
4$37,265$7,901.67$8,483$1,405.66+$28.8KSCPH
5$49,902$10,028.00$9,084$1,907.24+$40.8KSCPH
6$65,945$12,549.99$10,418$2,732.78+$55.5KSCPH
7$86,061$15,499.75$13,007$4,193.56+$73.1KSCPH
8$110,989$18,904.51$18,010$7,005.87+$93.0KSCPH
9$141,544$22,785.49$28,216$12,979.89+$113.3KSCPH
10$178,609$27,157.20$51,081$27,210.54+$127.5KSCPH

SCPH vs PFE: Complete Analysis 2026

SCPHStock

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Full SCPH Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SCPH vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SCPH vs SCHDSCPH vs JEPISCPH vs OSCPH vs KOSCPH vs MAINSCPH vs JNJSCPH vs MRKSCPH vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.